Navigation Links
Free DXA Bone Mineral Density and Body Composition in Clinical Trials Webinars to be Held by M2S DXA Division Expert
Date:1/27/2009

M2S Inc., a global provider of image management services for biopharmaceutical and medical device clinical trials, announced today that the company will be holding two free webinars to discuss how state-of-the-art image management can enhance DXA (Dual Energy X-Ray Absorptiometry) quality assurance services for bone mineral density trials and issues to consider in trials using body composition measurements with DXA.

(PRWEB) January 27, 2009 -- M2S Inc., a global provider of image management services for biopharmaceutical and medical device clinical trials, announced today that the company will be holding two free webinars to discuss how state-of-the-art image management can enhance DXA (Dual Energy X-Ray Absorptiometry) quality assurance services for bone mineral density trials and issues to consider in trials using body composition measurements with DXA.

On February 3, 2009 (1:00pm EST), an expert from M2S' DXA Division will present the benefits of electronic image transfer, real-time web-based tracking and processing of DXA bone mineral density images and discuss the potential time and cost savings. The second webinar, to be held February 10 (1:00pm EST), will provide useful information on potential challenges and issues in clinical trials using body composition measurements such as patient positioning, use of phantoms, analysis and outcomes decisions.

DXA (Dual- Energy X-Ray Absorptiometry) is a low-dose (1/10th of traditional x-ray) imaging modality that measures bone mineral density and body mass composition. It is increasingly utilized in clinical trials to assess the safety and effectiveness of drugs under development for osteoporosis, HIV, obesity, oncology, as well as hormonal therapies and pediatric indications.

"These webinars will provide insight and advice on how electronic image transfer can improve the speed and reduce the costs of collecting DXA images in clinical trials and provide useful information for planning trials using body composition," said Reta Rupich, Vice President, M2S DXA division.

To sign up for one or both free webinars, go to our DXA Webinar Sign up Page

About M2S, Inc.:
M2S provides image and data management services for clinical trials sponsors in the biopharmaceutical and medical device industries, patient registry databases and is a recognized leader in 3-D endovascular treatment planning. On December 31, 2008 M2S acquired DXA Resource Group (DRG), a clinical trials service company focused on providing customer-centric, cost-effective quality assurance as well as data and project management for clinical trials involving DXA measurements. For the past 10 years, M2S has managed, under protocol, millions of images from around the globe in various therapeutic areas and in all DICOM modalities. For more information, visit www.m2s.com or www.dxaresourcegroup.com.

###

Read the full story at http://www.prweb.com/releases/electronic/imaging/prweb1917154.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Related biology technology :

1. New property found in ancient mineral lodestone
2. Study Finds Widespread Vitamin and Mineral Use Among Cancer Survivors, Although Benefits of Such Use Remain Unclear
3. New insight to demineralization
4. Sea urchin yields a key secret of biomineralization
5. South Africas Minister of Minerals and Energy Welcomes Denham Capital Investment in BioTherm Energy to Develop Power Generation Business
6. deCODE Discovers Common Genetic Variations Contributing to Low Bone Mineral Density and Risk of Osteoporosis
7. AIM Pharmakon (API) Announced a New Proprietary Premium-Quality Natural Concentrated Liquid Calcium and Mineral Supplement Now Available Direct to Consumers
8. 220 Companies Place Switzerland First in Biotech Density Per Capita
9. Genta Receives Notice of Allowances for European Patents Related to Composition and Processes for Tesetaxel, a Leading Oral Taxane
10. OREXIGEN(R) Therapeutics Receives Notice of Allowance for U.S. Patent Covering the Composition of Matter in OREX-003
11. XTL Biopharmaceuticals Receives Notice of Non-Compliance with Nasdaq Marketplace Rule Due to Changes in Board Composition
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Free DXA Bone Mineral Density and Body Composition in Clinical Trials Webinars to be Held by M2S DXA Division Expert 
(Date:2/17/2017)... , Feb. 17, 2017  Protagonist Therapeutics, ... data on its oral peptide drug candidates, PTG-100 ... of the European Crohn,s and Colitis Organization (ECCO).  ... Barcelona, Spain from February 15 ... detail preclinical data on Protagonist drug candidates PTG-100 ...
(Date:2/16/2017)... Arbor, MI (PRWEB) , ... February 16, 2017 , ... ... 5:00-7:00 p.m. The event will be held at Avomeen Analytical Services (4840 Venture ... by a MichBio member organization. They provide an opportunity to interact with peers, make ...
(Date:2/16/2017)... and GREENWICH, Conn. ... private investment firm focused on venture growth investments ... promotion of Josh Richardson , M.D. to ... investments in biotechnology companies.  He is a board ... important roles in Longitude,s investments in Aimmune Therapeutics, ...
(Date:2/16/2017)... 2017  ArmaGen, Inc., a privately held biotechnology ... severe neurological disorders, today reported preliminary evidence of ... company,s investigational therapy for the treatment of Hurler ... I, or MPS I). The initial results from ... today at the 13 th annual WORLD ...
Breaking Biology Technology:
(Date:1/21/2017)... , Jan 20, 2017 Research and ... Biometrics Market 2017-2021" report to their offering. ... The global voice recognition biometrics ... 2017-2021. The report covers the present scenario and ... 2017-2021. To calculate the market size, the report considers the revenue ...
(Date:1/18/2017)...  In vitro diagnostic (IVD) companies were very active ... and Kalorama Information expects that trend to continue – ... Generally, uncertainty in reimbursement and healthcare reform in ... the acquisitions landscape. Instead of looking to buy technology, ... outside of their home country and also to increase ...
(Date:1/12/2017)...  Trovagene, Inc. (NASDAQ: TROV ), a ... that it has signed agreements with seven strategic partners ... Middle East for commercialization of the ... wave of international distribution agreements for Trovagene,s CLIA based ... The initial partners will introduce Trovagene,s liquid biopsy ...
Breaking Biology News(10 mins):